Full Press Release Details
SOUTH SAN FRANCISCO, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the delivery of content on state-of-the-art research accepted at the International Society of Heart and Lung Transplants (ISHLT) annual meeting that was originally scheduled for April 22-25, 2020 in Montreal, Canada.
CareDx’s program will include two virtual abstract sessions with prominent authors delivering ten abstracts accepted for presentation at the ISHLT Annual Scientific Sessions, and a virtual symposium with leaders in the field of heart transplantation delivering cutting edge content on HeartCare, AlloMap, AlloSure, and RemoTraC.
“I am glad to see CareDx providing a platform to share some of the latest innovations in care for heart and lung transplant patients through virtual platforms,” said Jon Kobashigawa, MD, Cedars Sinai.
On Wednesday, April 22, 2020, 3:00 PM EDT, five abstracts will be presented:
Gene Expression Profile Scores with AlloMap are higher in malignancy – Kiran Khush, MD – Stanford
The Effect of Pre-Transplant MCS on AlloMap Gene Expression Profile scores and AlloSure Donor-Derived Cell-Free DNA – Nir Uriel, MD – Columbia
Correlation of Gene Expression Profile scores with AlloMap and CMV infection – Manreet Kanwar, MD – Allegheny
AlloSure Donor-Derived Cell-Free DNA is associated with CAV – Luise Holzhauser, MD – University of Chicago
AlloSure Donor-Derived Cell-Free DNA precedes graft dysfunction in AMR – Cassandra Buto-Colletti, DO – VCU
On Thursday, April 23, 2020, 3:00 PM EDT, a virtual symposium on HeartCare, RemoTraC, and HeartCare cases examples will be presented:
Jon Kobashigawa, MD - Cedars-Sinai
Mario Deng, MD - UCLA
Ashrith Guha, MD - Houston Methodist
Sandra Carey, PhD - Baylor
On Friday, April 24, 2020, 3:00 PM EDT, five abstracts will be presented:
Gene Expression Profile scores with AlloMap in combined heart-kidney transplant patients – Eugene DePasquale, MD – USC
Correlating AlloSure Donor-Derived Cell-Free DNA and IVUS – Nirav Raval, MD – Advent Health
Early Experience with AlloSure Donor-Derived Cell-Free DNA in lung transplant patients – Deborah Levine, MD – UT Health San Antonio
Experience with AlloMap Gene Expression Profiling in the pediatric heart transplant population – Thomas Zellers, MD – Dallas Children’s Hospital
Hepatitis C viremic donors and AlloSure Donor-Derived Cell-Free DNA as a marker of inflammation and graft injury – Mary Beth Maydosz, NP – INOVA
“We are proud to have had the most successful ISHLT abstract session to date, with over ten abstracts accepted. We look forward to also contributing to ISHLTv. These abstracts further solidify the immense value of the multimodal molecular diagnostic tools – HeartCare, AlloSure, and AlloMap – for the surveillance of heart transplant patients,” says Sham Dholakia, Senior Vice President of Medical Affairs at CareDx.
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Chief Marketing Officer